<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100230</url>
  </required_header>
  <id_info>
    <org_study_id>2543</org_study_id>
    <secondary_id>FD-R-002543</secondary_id>
    <secondary_id>5R01FD002543</secondary_id>
    <secondary_id>C-TX02-0704-0274</secondary_id>
    <nct_id>NCT00100230</nct_id>
  </id_info>
  <brief_title>DHA and X-Linked Retinitis Pigmentosa</brief_title>
  <official_title>Investigation of Effectiveness and Safety of High Dose Docosahexaenoic Acid (DHA) in X-Linked Retinitis Pigmentosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Foundation of the Southwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation Fighting Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Retina Foundation of the Southwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:

      Retinitis pigmentosa (RP) is characterized by progressive loss of visual function due to
      specific genetic mutations. This trial is focused on patients with one of the most severe
      forms of the disease, X-linked inherited RP (XLRP). This disease is characterized by early
      onset (typically loss of night vision as a child) followed by loss of peripheral vision as a
      teenager and young adult. There is no male-to-male transmission of the disease in the family.

      There is no cure for RP and treatment options are limited. Two clinical trials have not found
      a benefit from nutritional supplementation with the long-chain polyunsaturated fatty acid,
      docosahexaenoic acid (DHA), at low daily doses although there is evidence that it slows
      disease progression in certain instances. In this clinical trial, we propose that a high dose
      nutritional DHA supplement will slow the loss of visual function and preserve usable vision
      in patients with XLRP.

      This study is a 4-year placebo-controlled randomized clinical trial meaning that patients
      have a 50-50 chance of receiving placebo or experimental treatment. A total of 66 patients
      will be enrolled; 33 will receive placebo and 33 will receive the treatment. Entry criteria
      include diagnosis of XLRP by an ophthalmologist, age 7 to 32 years, male, sufficient visual
      function such that disease progression can be followed for the entire duration of the trial,
      and a willingness to visit the testing site (Dallas, TX) once a year.

      Annual visual function testing includes ETDRS visual acuity, full-field and multifocal
      electroretinography (ERG), static peripheral visual fields, and fundus photography. Cone ERG
      function is the primary outcome measure.

      Funding Source - FDA, Foundation Fighting Blindness, DSM Nutritionals
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Location &amp; Contact Information:

      Retina Foundation of the Southwest, 9600 N. Central Expressway, Suite 200, Dallas, TX 75231
      Contact: Dr. D. Hoffman (dhoffman@retinafoundation.org) or Dr. D. Birch
      (dbirch@retinafoundation.org).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of LOSS of 31 Hertz Cone Electroretinographic Function</measure>
    <time_frame>4 years</time_frame>
    <description>Hypothesis #1: Elevation of red blood cell-docosahexaenoic acid levels will slow the progressive loss of 31 hertz cone electroretinographic response in this 4-year trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of LOSS of Rod Electroretinographic Function</measure>
    <time_frame>4 years</time_frame>
    <description>Hypothesis #1: Elevation of red blood cell-docosahexaenoic acid levels will slow the progressive loss of rod electroretinographic response in this 4-year trial.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Loss of Peripheral Visual Fields</measure>
    <time_frame>4 years</time_frame>
    <description>Hypothesis: Elevation of red blood cell-docosahexaenoic acid levels will slow the progressive loss of peripheral visual fields in this 4-year trial.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>X-linked Genetic Diseases</condition>
  <arm_group>
    <arm_group_label>1.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Docosahexaenoic acid, dosage based on body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>corn/soy oil placebo; oil not containing DHA...dosage based on body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docosahexaenoic acid OR corn/soy oil placebo</intervention_name>
    <description>daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial</description>
    <arm_group_label>1.</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>DHA; omega-3 fatty acid</other_name>
    <other_name>OR RANDOMIZED TO corn/soy oil placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RP by a retinal specialist

          -  Clinical diagnosis consistent with X-linked inheritance

          -  Enrolling minors and young adults (early onset of X-linked disease; ages 7 to 32)

          -  Measurable cone ERG responses --patients with less than 0.64 microvolt response to
             31-Hz flicker will be excluded as they are more likely to become undetectable during
             the study

          -  Both eyes must meet entry criteria as both will be tested (i.e., no cataracts
             requiring surgery or retinal detachments).

          -  Media clarity sufficient for fundus photography

          -  Able to return to study site at yearly intervals

          -  Willing to supply blood samples at 6-month intervals

          -  Judiciously take the placebo or DHA supplement for the 4-year study duration

          -  Patient/parent/guardian understands and signs consent form.

        Exclusion Criteria:

          -  Excessive fish consumption (e.g., cold water fish such as salmon, tuna, sardines)
             and/or fish oil supplementation (or other oil containing DHA)

          -  Baseline RBC-DHA levels showing evidence of supplementation (a typical level of
             RBC-DHA in normals is about 3.8%)

          -  Chronic metabolic disease that may interfere with fatty acid metabolism or require
             anti-coagulant medication

        No ethnic or racial groups will be excluded.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>32 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis R. Hoffman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Foundation of the Southwest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.retinafoundation.org</url>
    <description>website for Retina Foundation of the Southwest</description>
  </link>
  <results_reference>
    <citation>Hoffman DR, Hughbanks-Wheaton DK, Pearson NS, Fish GE, Spencer R, Takacs A, Klein M, Locke KG, Birch DG. Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial. JAMA Ophthalmol. 2014 Jul;132(7):866-73. doi: 10.1001/jamaophthalmol.2014.1634.</citation>
    <PMID>24805262</PMID>
  </results_reference>
  <results_reference>
    <citation>Hughbanks-Wheaton DK, Birch DG, Fish GE, Spencer R, Pearson NS, Takacs A, Hoffman DR. Safety assessment of docosahexaenoic acid in X-linked retinitis pigmentosa: the 4-year DHAX trial. Invest Ophthalmol Vis Sci. 2014 Jul 11;55(8):4958-66. doi: 10.1167/iovs.14-14437.</citation>
    <PMID>25015354</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2004</study_first_submitted>
  <study_first_submitted_qc>December 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2004</study_first_posted>
  <results_first_submitted>August 25, 2014</results_first_submitted>
  <results_first_submitted_qc>March 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2015</results_first_posted>
  <disposition_first_submitted>September 17, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>October 10, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 5, 2013</disposition_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Retina Foundation of the Southwest</investigator_affiliation>
    <investigator_full_name>Dennis Hoffman</investigator_full_name>
    <investigator_title>Senior Research Scientist (Retina Foundation of the Southwest)</investigator_title>
  </responsible_party>
  <keyword>retina</keyword>
  <keyword>electroretinography</keyword>
  <keyword>clinical trial</keyword>
  <keyword>docosahexaenoic acid</keyword>
  <keyword>omega-3 fatty acid</keyword>
  <keyword>x-linked inheritance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1. Docosahexaenoic Acid (DHA) Arm</title>
          <description>Docosahexaenoic acid (an omega-3 polyunsaturated fatty acid) taken orally at a dosage of 30 mg/kg body weight/day for a 4-year duration trial.</description>
        </group>
        <group group_id="P2">
          <title>Corn/Soy Oil Placebo Arm</title>
          <description>Corn/soy oil placebo (oils not containing DHA); dosage based on body weight for 4-year trial</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>males with X-linked retinitis pigmentosa</population>
      <group_list>
        <group group_id="B1">
          <title>1. Docosahexaenoic Acid (DHA) Arm</title>
          <description>Docosahexaenoic acid (an omega-3 polyunsaturated fatty acid) taken orally at a dosage of 30 mg/kg body weight/day for a 4-year duration trial.</description>
        </group>
        <group group_id="B2">
          <title>Corn/Soy Oil Placebo Arm</title>
          <description>Corn/soy oil placebo (oils not containing DHA); dosage based on body weight for 4-year trial</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Ages 7 to 32 years</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.7" spread="7.8"/>
                    <measurement group_id="B2" value="16.2" spread="6.6"/>
                    <measurement group_id="B3" value="16.7" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of LOSS of 31 Hertz Cone Electroretinographic Function</title>
        <description>Hypothesis #1: Elevation of red blood cell-docosahexaenoic acid levels will slow the progressive loss of 31 hertz cone electroretinographic response in this 4-year trial.</description>
        <time_frame>4 years</time_frame>
        <population>Number of participants completing at least one year of trial (i.e., modified intent to treat cohort)</population>
        <group_list>
          <group group_id="O1">
            <title>DHA (Docosahexaenoic Acid)</title>
            <description>Oral Docosahexaenoic acid, dosage based on body weight
docosahexaenoic acid OR corn/soy oil placebo: daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Corn/Soy Oil)</title>
            <description>corn/soy oil placebo; oil not containing DHA...dosage based on body weight
docosahexaenoic acid OR corn/soy oil placebo: daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of LOSS of 31 Hertz Cone Electroretinographic Function</title>
          <description>Hypothesis #1: Elevation of red blood cell-docosahexaenoic acid levels will slow the progressive loss of 31 hertz cone electroretinographic response in this 4-year trial.</description>
          <population>Number of participants completing at least one year of trial (i.e., modified intent to treat cohort)</population>
          <units>log microvolts/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.028" spread="0.001"/>
                    <measurement group_id="O2" value="0.022" spread="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence analysis: standard power calculation of 20%; used 2-sided t-test</non_inferiority_desc>
            <p_value>0.30</p_value>
            <p_value_desc>Threshold for significance: p&lt;0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of LOSS of Rod Electroretinographic Function</title>
        <description>Hypothesis #1: Elevation of red blood cell-docosahexaenoic acid levels will slow the progressive loss of rod electroretinographic response in this 4-year trial.</description>
        <time_frame>4 years</time_frame>
        <population>Number of participants completing at least one year of trial (i.e., modified intent to treat cohort)</population>
        <group_list>
          <group group_id="O1">
            <title>DHA (Docosahexaenoic Acid)</title>
            <description>Oral Docosahexaenoic acid, dosage based on body weight
docosahexaenoic acid OR corn/soy oil placebo: daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Corn/Soy Oil)</title>
            <description>corn/soy oil placebo; oil not containing DHA...dosage based on body weight
docosahexaenoic acid OR corn/soy oil placebo: daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of LOSS of Rod Electroretinographic Function</title>
          <description>Hypothesis #1: Elevation of red blood cell-docosahexaenoic acid levels will slow the progressive loss of rod electroretinographic response in this 4-year trial.</description>
          <population>Number of participants completing at least one year of trial (i.e., modified intent to treat cohort)</population>
          <units>change in amplitude, log microvolts/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.001"/>
                    <measurement group_id="O2" value="0.023" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence analysis: standard power calculation of 20%; used 2-sided t-test</non_inferiority_desc>
            <p_value>0.27</p_value>
            <p_value_desc>Threshold for significance: p&lt;0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence analysis: standard power calculation of 20%; used 2-sided t-test</non_inferiority_desc>
            <p_value>0.27</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Loss of Peripheral Visual Fields</title>
        <description>Hypothesis: Elevation of red blood cell-docosahexaenoic acid levels will slow the progressive loss of peripheral visual fields in this 4-year trial.</description>
        <time_frame>4 years</time_frame>
        <population>Only participants completing at least one year of trial</population>
        <group_list>
          <group group_id="O1">
            <title>DHA (Docosahexaenoic Acid) ARM</title>
            <description>Oral Docosahexaenoic acid, dosage based on body weight
docosahexaenoic acid OR corn/soy oil placebo: daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Corn/Soy Oil) ARM</title>
            <description>corn/soy oil placebo; oil not containing DHA...dosage based on body weight
docosahexaenoic acid OR corn/soy oil placebo: daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial</description>
          </group>
        </group_list>
        <measure>
          <title>Loss of Peripheral Visual Fields</title>
          <description>Hypothesis: Elevation of red blood cell-docosahexaenoic acid levels will slow the progressive loss of peripheral visual fields in this 4-year trial.</description>
          <population>Only participants completing at least one year of trial</population>
          <units>decibels (dB)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4" spread="3.2"/>
                    <measurement group_id="O2" value="112.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence analysis: standard power calculation of 20%; used 2-sided t-test</non_inferiority_desc>
            <p_value>0.000008</p_value>
            <p_value_desc>Threshold for significance: p&lt;0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <desc>Adverse events criteria were based on: Division of AIDS (DAIDS) National Institutes of Health. Table for grading severity of adult and pediatric adverse events (Dec 2004; rev. 2009) (http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf). Date of last access: 3-19-2014.</desc>
      <group_list>
        <group group_id="E1">
          <title>1. Docosahexaenoic Acid (DHA) Arm</title>
          <description>Docosahexaenoic acid (an omega-3 polyunsaturated fatty acid) taken orally at a dosage of 30 mg/kg body weight/day for a 4-year duration trial.</description>
        </group>
        <group group_id="E2">
          <title>Corn/Soy Oil Placebo Arm</title>
          <description>Corn/soy oil placebo (oils not containing DHA); dosage based on body weight for 4-year trial</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>DAIDS</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low HDL cholesterol</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>elevated LDL cholesterol</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>elevated total cholesterol</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>elevated potassium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>elevated glucose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach ache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A lower than expected event rate for the primary outcome measure was the major trial limitation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dennis Hoffman, Ph.D., Sr. Research Scientist</name_or_title>
      <organization>Retina Foundation of the Southwest</organization>
      <phone>214-363-3911 ext 125</phone>
      <email>dhoffman@retinafoundation.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

